SG3 Management’s GSK GSK Stock Holding History

SG3 Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,000	Closed	-$178K	–	1146
2021 Q1	$178K	Buy	+4,000	New	+$182K	﹤0.01%	986

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SG3 Management's GSK Position: Q2 2021 in Review

SG3 Management sold out of GSK (GSK) in Q2 2021, closing a stake of 4,000 shares — an estimated $178K sold.

SG3 Management first reported a position in GSK in Q1 2021 and held it in 1 quarter. The position peaked at $178K in Q1 2021. 798 funds tracked by Wall St. Rank hold GSK as of Q2 2021.

SG3 Management reported no remaining GSK position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 4,000 GSK shares in Q2 2021, an estimated $178K.
SG3 Management first reported a position in GSK in Q1 2021 and held it in 1 quarter.
SG3 Management's GSK position peaked at $178K in Q1 2021.
798 funds tracked by Wall St. Rank held GSK as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.